July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
NEI regenerative medicine program updates on AGI & 3DROC
Author Affiliations & Notes
  • Paul Sieving
    National Eye Institute, Bethesda, Maryland, United States
  • Footnotes
    Commercial Relationships   Paul Sieving, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3903. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Paul Sieving; NEI regenerative medicine program updates on AGI & 3DROC. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3903.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Presentation Description : The National Eye Institute (NEI) has two Director’s Initiatives that focus on regenerative medicine: the Audacious Goals Initiative (AGI) and the 3-D Retina Organoid Challenge (3D ROC). The NEI AGI continues to pursue its goal to regenerate neurons and their neural connections in the eye and visual system. The initiative issued its third funding opportunity in December of 2017 which solicited applications to develop robust translational models that can inform the study of stem cell replacement strategies. The initiative is focused on translating promising preclinical regenerative medicine studies into clinical trials that will touch patients. To inform this objective NEI has brought on new AGI Steering Committee members. In the spring of 2017, NEI announced the 3D Retina Organoid Challenge which asked for new ideas to produce functional 3-dimensional human retinas that could be used for disease modeling or drug testing. In September 2017, Erin Lavik of University of Maryland Baltimore County was awarded $90,000 for an innovative idea to use screen printing methods to build retina organoids. The NEI has now launched a second competition, 3D ROC 2020, which calls for the generation of 3-D retinal organoids and demonstration that they function as disease models or drug screening tools. The preliminary submission period ends October 1, 2018 and the final submission date is March 2, 2020 with up to $1 million in prizes available.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×